According to guidelines from the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO), the standard treatment for DKD combines renin-angiotensin system inhibitors (ACE inhibitors or angiotensin receptor blockers) with cardiorenal protective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (ns-MRA), and glucagon-like peptide-1 receptor agonists (GLP-1R). This evidence concerns the gene GLP1R and diabetic kidney disease.